Moreover, anti-CD19/BAFF-R CAR-T cell therapy showed prolonged in vivo persistence and exhibited antigen-specific cytokine release, degranulation, and cytotoxicity against both CD19-/- and BAFF-R-/- variant human ALL cells in vitro (176). Here, CD19 is linked to acute lymphoblastic leukemia.